Nigeria is set to take a major step forward in HIV prevention as the Federal Government announces plans to introduce a groundbreaking long-acting prevention drug, Lenacapavir, in March 2026.
According to the (NACA), consignments of Lenacapavir (LEN) are expected to arrive in the country in March, marking a significant milestone in Nigeria’s efforts to curb new HIV infections and accelerate progress toward epidemic control.
What Is Lenacapavir?
Lenacapavir is a long-acting HIV prevention medication used as pre-exposure prophylaxis (PrEP). Unlike daily oral PrEP options, Lenacapavir is administered as an injection only twice a year, offering a more convenient alternative for individuals at risk of HIV infection.
Clinical trials have shown that Lenacapavir significantly reduces the risk of HIV infection, providing almost total protection when used as directed. This innovation is expected to improve adherence rates and expand access to effective prevention for populations who may struggle with daily medication.
Government’s Commitment to HIV Prevention
In a statement released on March 2, NACA confirmed that the Government of Nigeria (GON) is advancing preparations for the structured introduction and rollout of Lenacapavir as PrEP.
The agency emphasized that this move is part of the government’s broader commitment to strengthening HIV prevention strategies and achieving epidemic control nationwide.
“Commodities are expected in country in March 2026,” the statement noted, signaling that preparations are already in advanced stages.
Phased Rollout in Priority States
NACA revealed that Nigeria will adopt a phased introduction approach, ensuring a quality-assured and well-coordinated rollout. Landscape and readiness assessments have already been completed in 10 priority states:
- Akwa Ibom
- Anambra
- Benue
- Cross River
- Ebonyi
- FCT
- Gombe
- Kano
- Kwara
- Lagos
These assessments evaluated service delivery capacity and identified specific implementation needs in each state.
Capacity Building and Community Engagement
To ensure smooth implementation, NACA has conducted a national training of trainers in Abuja, followed by step-down training sessions for healthcare workers in the selected states.
Additionally, information, education, and communication (IEC) materials have been developed to support public awareness and community engagement ahead of the rollout.
What This Means for Nigeria
The introduction of Lenacapavir represents a transformative shift in HIV prevention in Nigeria. By offering a twice-yearly injectable option, the country is expanding access to innovative, user-friendly prevention tools that could significantly reduce new infections.
As March 2026 approaches, stakeholders across the health sector are working to ensure that the rollout is structured, inclusive, and impactful — bringing Nigeria one step closer to ending the HIV epidemic.
